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Pathophysiology

Introduction
Systemic lupus erythematosus (SLE) is a challenging auto-immune disorder
that incurs sporadic flares, remissions, and relapses (Robinson & Currie, 2011, p.
629). This auto-immune process is caused by the lack of tolerance to self-antigens
within the adaptive immune system and can involve multiple organ systems,
including the brain, heart and kidneys (Chen, Wu, Wang, Li, 2015, p. 1). SLE, also
referred to as lupus, is a disease that affects women more often than men,
especially during their childbearing years (Robinson & Currie, 2011, p. 631).
Over the past 3 decades, the five-year survival rate for patients suffering from
Lupus have increased from 50% to 95% with decreasing deaths from infection
and renal disease (Weinstein et al., 2014, p. 130). Cardiovascular disease,
however, continues to be a main cause of death for those diagnosed from SLE
(Gilbert & Ryan, 2014, p. 1902). The cardiovascular system is known to be a
potential target for patient with lupus, causing 7- to 10-fold increase in
cardiovascular disease (CVD) (Weinstein et al., 2014, p. 130). Complications of
CVD include pericarditis, valvular and atherosclerotic changes. Women with SLE,
however, are unaware of the increased risk of cardiovascular disease associated
with lupus (Weinstein et al., 2014, p.130).
SLE can be masked by the signs and symptoms of other superficial disease
processes, while the underlying etiology is auto-immune (Weinstein, 2012, p. 38).
Understanding the pathophysiology of SLE can aid in early diagnosis and
treatment to provide better long-term patient outcomes and improve quality of
life.

Signs & Symptoms
SLE can be difficult to diagnose as many symptoms are vague and non-specific,
such as fatigue, joint pain, fever and recurrent infections. Females are at a higher
risk of developing SLE than males by a 9:1 ratio (Weinstein, 2012, p. 39).
Currently, there is no formal diagnostic test for SLE, however, the American
College of Rheumatology have developed a list of criteria to help diagnose
patients with lupus.

The pathophysiology of SLE occurs at both the cellular and tissue level. The cellular level refers to the production and
tolerance of auto-antibodies. The clinical manifestations of SLE occur at the tissue level by the formation of immune
complexes that accumulate and deposit in organ tissues.
Cellular level.











•

Malar Rash
Discoid Rash
Photosensitivity
Oral ulcers
Arthritis
Serositis
Persistent protein in the urine
Seizures or psychosis
Blood disorders: anemia, leukopenia, lymphopenia, thrombocytopenia
Immunologic disorders: positive anti-double-stranded DNA (antidsDNA), anti-Sm, antiphospholipid antibodies (aPL)
Positive antinuclear antibody (ANA) test



Figure 2. Pathophysiology of SLE
(Tsokos, 2011, p. 2112)

Significance of Pathophysiology






Figure 1. Malar Rash
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SLE is referred to as a type III hypersensitivity with the
production of immune complexes that are deposited into
peripheral tissues. Immune complexes are composed of
multiple auto-antibodies and self-antigens that are
circulating within the blood stream (Liao, Reihl, & Luo,
2016, p. 1).
Once the immune complexes are deposited into the
tissues, the compliment system is activated which
ultimately instigates the innate inflammatory response
and promotes tissue damage (Liao, Reihl, & Luo, 2016, p.
1).

Understanding the pathophysiology of auto-immune
disorders, such as SLE, aids in the screening, diagnosis and early
treatment to decrease the progression of SLE. Using solely the
traditional Framingham risk factors for cardiovascular disease in
patients with SLE is ineffective in providing appropriate
preventative therapy (McMahon et al., 2014, p. 131).
Healthcare professionals should screen for cardiovascular risk
factors in patients with SLE, including (Turano, 2013, p. 51):








Tissue level.

Four of the following symptoms must be present for the formal diagnosis of
Lupus (Weinstein, 2012, p. 39):
•
•
•
•
•
•
•
•
•
•

Abnormal activation of T and B cells, along with altered
signaling events within the cell are characteristic in those
with SLE (Tsokos, 2011, p. 2111).
Signaling abnormalities within the cell lead to a deficiency
of the interleukin-2 (IL-2) cytokine, causing a decrease in
efficacy of the cytotoxic T-cell and a decrease in apoptosis
of the auto-reactive T cells (Tsokos, 2011, p. 2111).
T cells migrate to inflamed areas of the body and have a
heightened expression of the CD44 adhesion molecules,
facilitating attachment to the endothelial lining of the
blood vessel (Tsokos, 2011, p. 2112).
Plasma cells are responsible for antibody production and
are increased during the active stage of SLE (Tsokos,
2011, p. 2112). An increased production of auto-reactive
antibodies correlates to the expression/flares of SLE.
The immune response is limited/controlled by the
expression of Treg cells. Patients with SLE have decreased
and/or dysfunctional Treg cells, which contribute to the
pathogenesis of SLE (Moulton & Tsokos, 2015, p. 2224).

Implications for Nursing Care

According to the CDC (2015), prevalence and incidence rates for SLE are difficult to predict due to the non-specific nature of presenting
symptoms. Prevalence rates have varied in the United States from 161,000 to 1.5 million cases. Family history is a strong predictive value
for development of lupus with more than 20 different genetic abnormalities identified (Weinstein, 2012, p. 40).
Auto-antibodies in patients with SLE are thought to be the initial causative agent associated with endothelial damage (Turano, 2013, p.
50). Several different auto-antibodies have been identified in the pathogenesis of SLE, including anti-dsDNA, antiphospholipid (aPL), antiSm and ANA (Weinstein, 2012, p. 42).
Overexpression of antibody adhesion molecules promotes endothelial damage, leading to atherosclerosis (Tsokos, 2011, p. 2112). The
extent of atherosclerosis is directly correlated to the duration of SLE symptoms (Turano, 2013, p. 49)
Epigenetic changes can alter the functionality of T cells and instigate the auto-immune response in SLE (Moulton & Tsokos, 2015, p.
2225). According to Moulton & Tsokos (2015), hypomethylation of numerous genes, including CD11A, perforin, CD70, and CD40L, have
been implicated in the development of SLE (p. 2225).
The focus of treatment is associated with limiting the effect of inflammation on local tissues to prevent damage with non-steroidal antiinflammatory drugs (NSAIDS), corticosteroids, antimalarial and immunosuppressive agents (Turano, 2013, p. 49).

Hypertension
Dyslipidemia
Diabetes Mellitus
Obesity
SLE disease activity
Renal function
Antiphospholipid or lupus anticoagulant levels

Preventative screenings provide better identification of high
risk patients and enable early preventative care. In addition,
education should be provided to all patients regarding the risk of
cardiovascular disease. Focus should be placed upon modifiable
risk factor management of blood pressure, weight, smoking
status, and activity level.
Treatment using aggressive blood pressure management
should be maintained in patients with SLE. Use of a multi-drug
regimen, including angiotensin-converting enzyme (ACE)
inhibitors, and thiazide diuretics, may be necessary to control
hypertension (Turano, 2013, p. 52). The use of beta-blockers can
precipitate Raynaud’s phenomenon in patients with SLE and
should be utilized only as a second-line treatment (Turano, 2013,
p. 51). Corticosteroids are considered to be the gold standard
treatment in SLE. Long-term use of corticosteroids, however,
increases the risk of developing insulin resistance and obesity,
thereby, increasing the risk of cardiovascular disease (Turano,
2013, p. 51). Utilizing individualized plans of care better tailor
treatment to each patient with SLE, improving the efficacy of
treatment and prolonging the progression of SLE.

Conclusion
Systemic Lupus Erythematosus is difficult to diagnose as
many symptoms are non-specific, including fatigue, joint pain
and fever (Weinstein, 2012, p. 38). A comprehensive history
and physical assessment should be performed by a healthcare
practitioner to determine possible risk for SLE (Weinstein,
2012, p. 39). Early screening and diagnosis, as well as,
appropriate risk factor management strategies have improved
long-term patient outcomes. Progressive treatment plans for
patients with SLE has improved life expectancy and quality of
life (Turano, 2013, p. 48). Cardiovascular disease and
atherosclerosis are becoming the leading cause of death
amongst patients with SLE and have been attributed to the new
successful treatment options and improved life expectancy
(Gilbert & Ryan, 2014, p. 1902). Healthcare providers should
focus on patient education regarding increased risk for
cardiovascular disease associated with SLE and risk factor
management (Weinstein, Amirkhosravi, Angelopoulos, Bushy,
Covelli & Dennis, 2014, p. 137).
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